Therapeutic targeting and patient selection for cancers with homologous recombination defectsTalens, F., Jalving, M., Gietema, J. A. & Van Vugt, M. A. Jun-2017 In : Expert Opinion on Drug Discovery. 12, 6, p. 565-581 17 p.
Research output: Scientific - peer-review › Literature review
Introduction: DNA double-strand breaks (DSBs) are toxic DNA lesions that can be repaired by non-homologous end-joining (NHEJ) or homologous recombination (HR). Mutations in HR genes elicit a predisposition to cancer; yet, they also result in increased sensitivity to certain DNA damaging agents and poly (ADP-ribose) polymerase (PARP) inhibitors. To optimally implement PARP inhibitor treatment, it is important that patients with HR-deficient tumors are adequately selected.
Areas covered: Herein, the authors describe the HR pathway mechanistically and review the treatment of HR-deficient cancers, with a specific focus on PARP inhibition for BRCA1/2-mutated breast and ovarian cancer. In addition, mechanisms of acquired PARP inhibitor resistance are discussed. Furthermore, combination therapies with PARP inhibitors are reviewed, in the context of both HR-deficient and HR-proficient tumors and methods for proper patient selection are also discussed.
Expert opinion: Currently, only patients with germline or somatic BRCA1/2 mutations are eligible for PARP inhibitor treatment and only a proportion of patients respond. Patients with HR-deficient tumors caused by other (epi)genetic events may also benefit from PARP inhibitor treatment. Ideally, selection of eligible patients for PARP inhibitor treatment include a functional HR read-out, in which cancer cells are interrogated for their ability to perform HR repair and maintain replication fork stability.
|Number of pages||17|
|Journal||Expert Opinion on Drug Discovery|
|State||Published - Jun-2017|
- BRCA1, BRCA2, genome instability, homologous recombination, Lynparza, olaparib, PARP inhibitor, personalized medicine, synthetic lethality, NEGATIVE BREAST-CANCER, DNA END RESECTION, DOUBLE-STRAND BREAKS, EMBRYONIC CELLULAR PROLIFERATION, OLAPARIB MAINTENANCE THERAPY, RANDOMIZED PHASE-2 TRIAL, SENSITIVE OVARIAN-CANCER, BRCA2 MUTATION CARRIERS, FANCONI-ANEMIA PATHWAY, EX-VIVO ASSAY